HeartCare Medical-B (06609.HK) Surges Over 10% Ahead of Earnings on Strong H1 Profit Guidance

According to the Zhongtong Finance APP, HeartCare-B (06609) surged over 10%. As of press time, it rose 10.3% to HK$56.75, with a turnover of HK$13.4465 million.

On the news front, HeartCare will hold a board meeting today to review and approve the interim results of the company and its subsidiaries for the six months ended June 30, 2025, and their publication. The company previously announced that it expects to achieve a net profit attributable to shareholders of no less than RMB 40 million in the first half of 2025, turning losses into profits. This is mainly due to increased revenue driven by sales of newly launched hemorrhagic stroke treatment devices, acute ischemic stroke treatment devices, and other hemorrhagic stroke treatment devices. Effective cost control measures for sales and administrative expenses have reduced the group's overall expense ratio, and changes in the research phase of the group’s R&D projects have led to decreased R&D expenditures. Additionally, there was an increase in fair value gains from financial assets measured at fair value through profit or loss.